This week Bitcoin (BTC) and choose altcoins broke above their quick resistance ranges and moved increased, which propelled the whole crypto market capitalization above $2 trillion on March 24. One of the triggers that could have driven crypto prices higher was BlackRock CEO Larry Fink’s letter to shareholders the place he mentioned that the Russia-Ukraine […]
Since January 2021, the oil and gas giant ExxonMobil has been operating a pilot project to power Bitcoin mining operations. Overview of the Pilot Project The pilot project’s objective is to utilize ‘wasted gas’ from its North Dakota oil wells to power Bitcoin mining operations. ExxonMobil, the largest oil producer in the United States, intends to expand the project into other nations as well. These include Nigeria’s Qua Iboe Terminal, Argentina’s Vaca Muerta Shale formation, as well as Alaska, Guyana, and Germany. Reportedly, each month the project consumes 18 million cubic feet of natural gas. Due to a shortage of pipelines, the extra natural gas would normally be burned or flared. New Partnership for ExxonMobil ExxonMobil also unveiled an arrangement with Crusoe Energy Systems that allows the latter to power mobile generators. These are utilized for the Bitcoin mining servers on-site with the gas derived from Bakken Shale Oil Wells. A representative of ExxonMobil disclosed in a statement that the multination conglomerate had been continually looking for ways to reduce its gas flaring volumes. However, ExxonMobil’s spokesperson denied clarifications on the company’s need to utilize natural gas for Bitcoin mining. In conclusion, there have been multiple research papers emphasizing the role of Bitcoin mining in promoting renewable energy sources. Thereby, using natural gases that could be flared can assist in lessening the impact of the process on the environment, leading to a win-win scenario.
Korea-based gaming developer and publisher Krafton announced its new collaboration with blockchain platform in a concerted effort to develop Play-to-Earn blockchain and NFT games. Krafton is the name behind popular game titles such as PUBG: Battlegrounds, Thunder Tier One, Elyon, and many more. According to the announcement on March 23, Krafton and Solana Labs signed [...]
TOKYO, Mar 25, 2022 - (JCN Newswire) - JTOWER Inc. ("JTOWER") and NTT DOCOMO, INC. ("DOCOMO") have announced today that the companies have decided to enter into the master transaction agreement with the aim of promoting Infra-Sharing of DOCOMO's existing towers. The contract will enable the companies to make a transaction in which 6,002 telecommunications towers (maximum) owned by DOCOMO to be transferred to JTOWER for 106.2 billion yen (maximum) and DOCOMO will lease these towers from JTOWER ("the Transaction").
Image of a telecommunications tower
Aims of both companies
JTOWER positions the purchase of existing telecommunications towers owned by telecommunications companies and the promotion of Infra-Sharing by attracting new tenants to these towers (carve-out) to be one of the key growth strategies. The Transaction will greatly expand its business foundation as a tower sharing operator.
DOCOMO is working to build an economical 5G network by promoting Infra-Sharing and the Transaction will enable further streamlining of network operations. Future Initiatives
The companies plan to make the transfer of the towers where conditions have been met and JTOWER will strengthen its efforts to attract new tenants, such as telecommunications companies, including mobile network operators. Through these efforts, both companies aim to realize more efficient capital investments and operating expenses for the tenants of these towers and promote the early deployment of 5G network. Furthermore, the companies will contribute to the realization of a sustainable society by reducing environmental impact through the effective use of existing infrastructure.
JTOWER and DOCOMO will continue to strengthen collaboration in the field of Infra-Sharing and work to resolve social issues that contribute to the telecommunications industry.
JTOWER Inc. was founded in June 2012 as the first Infra-Sharing company in Japan. Centered on indoor Infra-Sharing solutions that consolidate the mobile networks inside the building, we provide a wide range of services including 5G that contribute to the future. https://en.jtower.co.jp/
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 83 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations. https://www.docomo.ne.jp/english/.
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comJTOWER Inc. and NTT DOCOMO, INC. have announced today that the companies have decided to enter into the master transaction agreement with the aim of promoting Infra-Sharing of DOCOMO's existing towers.
HONG KONG, Mar 25, 2022 - (ACN Newswire) - Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%. Revenue from non-COVID-19-related testing services was RMB868.57 million, an increase of 12.3%. The Group's consolidated gross profit was up by 5.4% year-on-year to RMB485.77 million, while the consolidated gross profit margin rose by 0.5% year-on-year to 52.2%. Cash and cash equivalents amounted to RMB1,796.7 million, a growth of 113.6% year-on-year. The non-COVID-19-related testing services segment recorded results of RMB197.18 million, an increase of 17.5% year-on-year. The Board has resolved not to distribute a dividend for FY2021.
Focused on specialty esoteric testing services and vigorously developed related services in six major specialty areas
Since its inception in 2003, the Group has been focusing on esoteric clinical testing services and is one of the first companies in China entering the esoteric testing service industry. During the period under review, the Group covered more than 3000 hospitals, in which over 60% are Class III hospitals, added three new laboratories and its esoteric testing volume exceeded 1.68 million, with positive growth in all six major esoteric testing specialty areas.
-- Hematology testing: The Group introduced 50 new testing items and added the Shanghai Xinnuo Baishi Medical Laboratory. During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively. -- Neurology testing: The Group launched six new projects covering diseases such as Alzheimer's disease and myasthenia [gravis] and also added 143 partnering Class III hospitals. The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively. -- Maternity-related testing: The Group added the diagnosis of gestational syndromes during the period, and recorded revenue of RMB52.25 million and segment results of RMB3.55 million, representing a year-on-year increase of 0.2% and 0.5%, respectively. -- Genetic disease and rare disease testing: During the period, the Group realized revenue of RMB43.50 million and segment results of RMB5.43 million, representing a year-on-year increase of 20.2% and 126.4%, respectively. Sales of multiple steroid hormone tests doubled year-on-year. -- Infectious disease testing: The Group introduced 28 new testing items and added the Wuhan Kindstar Zhenyuan Medical Laboratory, achieving revenue of RMB51.97 million and segment results of [RMB]9.78 million during the period, representing a year-on-year increase of 3% and 33.2%, respectively. -- Oncology testing: The Group launched new testing service items for various types of cancer, including intestinal cancer, cervical cancer, bladder cancer and liver cancer, achieving revenue of RMB8.62 million and segment results of RMB0.83 million during the period, 13.4% and 82.5% higher than the same period last year. -- Others: The Group added more than 20 scientific research service projects in the areas of research services, CRO and new testing services, achieving revenue of RMB19.46 million and segment results of RMB5.99 million during the period, representing a year-on-year growth of 36.1% and 35.1%, respectively.
Persistent R&D investment to develop and expand new specialty esoteric testing business lines
As at 31 December 2021, the Group's R&D expenses amounted to RMB90.33 million, a year-on-year increase of 20.0%.The Group had 112 new R&D projects, 17 patents were pending or granted and 23 scientific research articles were published throughout the year. During the period under review, the Group stepped up its efforts in promoting the development of specialty esoteric testing services in China and expanding the scope of such services to cover cardiovascular diseases, ophthalmology, rheumatology and immunology.
-- Cardiovascular diseases: The Group focused on the R&D of biomarkers for cardiovascular diseases such as coronary heart disease, acute myocarditis and acute myocardial infarction. It also conducted verification studies on the clinical value of biomarkers. -- Ophthalmology: The Group actively explored opportunities in ophthalmic structured esoteric testing services and its R&D covered testing solutions for hereditary oculopathy, infectious oculopathy and autoimmune oculopathy. -- Rheumatology and immunology: The Group began the initial development of six types of disease and drug detection projects, covering sicca syndrome, rheumatoid arthritis, ankylosing spondylitis, gout, antiphospholipid syndrome and allopurinol detection.
Entered the IVD reagents field and optimized immune repertoire deployment
Wuhan Haixi Life Science Technology Co., Ltd., which the group owns a controlling stake, is a high-tech enterprise based on the R&D, manufacturing and sales of esoteric testing reagents providing systematic, comprehensive "high-precision and cutting edge" testing reagent products. The Group's main products, namely reagent kits for JAK2 genes and V617F mutations (PCR-fluorescent probe method) and reagent kits for leukemia fusion genes qualitative testing (PCR-fluorescent probe method) will enter the clinical trial stage of NMPA registration. During the period under review, the Group established its business presence in the field of IVD reagent kits in the upstream industry chain by holding shares in Wuhan Haixi Life Science Technology Co., Ltd.
As an important next-generation sequencing technology, the immune repertoire sequencing technology may bring disruptive changes to the industry in the future. During the period under review, the Group established Wuhan Kindstar Biotechnology Co., Ltd., which will focus on the application and development of the immune repertoire technology in multiple disciplines and explore the biopharmaceutical and immunotherapy pathways. In addition, to further improve its immune repertoire layout, the Group invested in Shenzhen Neoimmune Co., Ltd., a leading immune repertoire enterprise in China. Looking ahead, the two parties will commence strategic cooperation in the immune repertoire segment.
Strategy and Prospects
The Group will continue to consolidate its leading position in esoteric hematology testing in China and replicate its successful experience in hematology to expedite the growth of its specialty esoteric testing business in areas such as genetic diseases, rare diseases, infectious diseases, oncology and neurology. In the next three to five years, the Group will enter several new areas of specialty esoteric testing. At the same time, the Group is also committed to building strong relationships with a wide range of participants in the clinical esoteric testing industry (including doctors, hospitals, pharmaceutical companies, contract research institutions, academic institutions and regulatory agencies), deepening existing strategic partnerships, and expanding the existing cooperation network. Since its listing, the Group has attached great importance to opportunities for horizontal and vertical integration in the industrial chain. In the future, the Group will steadily achieve a strategic and forward-looking layout through investment, integration and empowerment, in order to boost its growth.
Huang Shiang, Chairman and Chief Executive Officer of Kindstar Globalgene, expressed full confidence in the future of China's esoteric clinical testing industry. He said, "Due to increasing public health awareness and an aging population in China, the demand for clinical tests has continued to increase. In recent years, China's esoteric clinical testing market has been growing faster than its routine testing market, and the Company has strived to develop and introduce advanced technologies to meet the enormous unmet medical demand in the country. Looking ahead, we will actively overcome the various uncertainties caused by the COVID-19 pandemic, while continuing to work hard to maintain the steady growth of our existing esoteric clinical tests, and develop and launch new services in specialty areas, thereby contributing to the precise diagnosis and advancement of treatments in specialty areas in China."
About Kindstar Globalgene Technology, Inc. Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China. It has built a comprehensive testing portfolio, a broad hospital network and advanced technology platforms and also boasts the largest esoteric testing portfolio among all independent esoteric testing providers in China, with more than 3,500 tests on its service menu and offering one of the most extensive hematology testing portfolios worldwide, including over 2,300 testing items in the field. The Group primarily targets specialty areas with substantial growth potential or that can create significant synergies with its esoteric hematology testing services, including genetic diseases and rare diseases, infectious diseases, oncology and neurology. The Group was listed on the Main Board of the Hong Kong Stock Exchange on 16 July 2021. Over the past 18 years, the Company has developed more than 1,100 testing items entirely in-house, and introduced approximately 2,400 testing items developed by or under license from third parties. The Group serves more than 3,000 hospitals in China, of which more than 1,500 are Class III hospitals, including all of the top 20 hospitals in the nation. The Group's mission is to offer a broad range of high-quality specialty testing services to patients and physicians worldwide, and to promote the application of precision diagnostics and medicine.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
Tokyo and Salt Lake City, Indianapolis, Mar 25, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood glucose levels and avoid serious complications, such as loss of vision and kidney disease.
Image of the AI grouping patients and analyzing the treatment patterns & efficacy
For this smaller group of patients, physicians may have limited clinical decision-making experience or evidence-based guidance for choosing drug combinations. The solution is to expand the number of patients to support development of general principles to guide decision- making. Combining patient data from multiple healthcare institutions, however, requires deep expertise in artificial intelligence (AI) and wide-ranging experience in developing machine learning models using sensitive and complex healthcare data.
Hitachi, U of U Health, and Regenstrief researchers partnered to develop and test a new AI method that analyzed electronic health record data across Utah and Indiana and learned generalizable treatment patterns of type 2 diabetes patients with similar characteristics. Those patterns can now be used to help determine an optimal drug regimen for a specific patient.
Some of the results of this study are published in the peer-reviewed medical journal, Journal of Biomedical Informatics, in the article, "Predicting pharmacotherapeutic outcomes for type 2 diabetes: An evaluation of three approaches to leveraging electronic health record data from multiple sources". (bit.ly/3NvD7BE)
Hitachi had been working with U of U Health for several years on development of a pharmacotherapy selection system for diabetes treatment(1) . However, the system was not always able to accurately predict more complex and less prevalent treatment patterns because it did not have enough data. In addition, it was not easy to use data from multiple facilities, as it was necessary to account for differences in patient disease states and therapeutic drugs prescribed among facilities and regions. To address these challenges, the project partnered with Regenstrief to enrich the data it was working with.
The new AI method initially groups patients with similar disease states and then analyzes their treatment patterns and clinical outcomes. It then matches the patient of interest to the disease state groups and predicts the range of potential outcomes for the patient depending on various treatment options. The researchers evaluated how well the method worked in predicting successful outcomes given drug regimens administered to patients with diabetes in Utah and Indiana. The algorithm was able to support medication selection for more than 83 percent of patients, even when two or more medications were used together.
In the future, the research team expects to help patients with diabetes who require complex treatment in checking the efficacy of various drug combinations and then, with their doctors, deciding on a treatment plan that is right for them. This will lead not only to better management of diabetes but increased patient engagement, compliance, and quality of life.
The three parties will continue to evaluate and improve the effectiveness of the new AI method and contribute to future patient care through further research in healthcare informatics.
Hitachi will accelerate efforts, including the practical application of this technology through collaboration between its healthcare and IT business divisions and R&D group. GlobalLogic Inc., a Hitachi Group Company and leader in Digital Engineering, is promoting healthcare- related projects in the U.S., will also deepen the collaboration in this field. Through these efforts, the entire Hitachi group will contribute to the health and safety of people.
(1) Hitachi, Ltd. news release, March 12, 2018 "Pharmacotherapy Selection System Supports Shared Clinician- patient Decision-Making in Diabetes Treatment" bit.ly/3Ld97Z7 Hitachi, Ltd. news release, February 27, 2019 "New Clinical Study Tests Pharmacotherapy Selection System that Aims to Improve the Impact of Diabetes Treatment" bit.ly/3wJ1Ax4
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company's consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.
About University of Utah Health
University of Utah Health provides leading-edge and compassionate medicine for a referral area that encompasses 10% of the U.S., including Idaho, Wyoming, Montana and much of Nevada. A hub for health sciences research and education in the region, U of U Health has a $428 million research enterprise and trains the majority of Utah's physicians, including more than 1,250 health care providers each year at its Schools of Medicine and Dentistry and Colleges of Nursing, Pharmacy and Health. With more than 20,000 employees, the system includes 12 community clinics and four hospitals. For ten straight years, U of U Health has ranked among the top 10 U.S. academic medical centers in the Vizient Quality and Accountability Study.
About Regenstrief Institute
Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national, and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.
Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute's research mission.
Research & Development Group, Hitachi, Ltd. bit.ly/3qw4CRy
Regenstrief Institute 1101 West Tenth Street Indianapolis, IN 46202 John Erickson (317) 643-2313 firstname.lastname@example.org
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment.
Uniswap price analysis is bullish today as we expect more upside to follow after the trend rejected a downside last midnight. UNI/USD has since tested upside, with the current number of buyers in the market. Probably, if buyers remain strong there is a high likelihood that the bullish trend will continue. Uniswap has recently been on a downtrend since mid-January, we are expecting a turn soon with the bullish trend in the cryptocurrency market currently. Uniswap price movement in the last 24 hours: Uniswap retest downside, bullish trend continue UNI/USD traded in a range of $9.18- $9.89, indicating a moderate spike over the last 24hours. Trading volume has declined by 8.22percent, totaling $225 million. UNI/USD 4-hour chart: UNI seems to have a bullish trend In the 4hour chart, we can see the Uniswap price setting a higher low and a lower high indicating consolidation in an increasingly narrow range. UNI prices saw a sharp reversal this week after a continuous downtrend. What do influencers think about the price direction of Uniswap? Popular youtube analyst Crypto prince applauded Uniswap as one that was on its way to being the best altcoin. Uniswap operates on a decentralized P2P exchange automated market maker. The analyst also pointed out that the main feature that will contribute; to the rise of Uniswap is that being linked to Ethereum enabled two smart contracts to earn interests and provide liquidity directly from the liquidity providers. Uniswap currently trades at almost six times more than starting in 2022 so the trend may be seen till December 2022. Should you invest in Uniswap in 2022? Uniswap is a decentralized exchange coin linked with Ethereum. It has several unique features that enable it to provide liquidity directly from liquidity providers; therefore acting as a major catalyst in entirely removing the hurdle concerning token mining thus promoting transparency and eliminating the middlemen. Instead of the individual cryptocurrencies, the digital assets come in pairs hence the platform governs the liquidity for these parts; accordingly as a decentralized protocol for automated liquidity provisions on Ethereum. Uniswap launched this token during the pandemic on September 17, 2020; making millions for all those holding it. The vision of UNI stands tall and firm leaving behind footprints on the technological and functional eco-space.UNI nurtures hope along with convenience making the lives of the Uniswap users worldwide easy. The relationship between supply and demand is the age-old phenomenon of contradiction that works for UNI token whereby, traders come to the market with aspirations that the Uniswap cryptocurrency market they hold will promise great returns.
HONG KONG, Mar 24, 2022 - (ACN Newswire) - AGTech Holdings Limited ("AGTech" or the "Group", SEHK: 08279) announced today that it has completed the acquisition of Macau Pass Holding Ltd. ("Macau Pass") and its subsidiaries, which will become an indirect wholly-owned subsidiary of AGTech after completion of the transaction.
Since granted the financial license by the Macau SAR Government in 2006, Macau Pass has been propelling the development of a more convenient local electronic payment and promoting its popularity in Macau. Macau Pass, being the leading payment service provider in Macau, issued the first and the most commonly used contactless smart card for payments in Macau, Macau Pass Card ("MP Card"). While initially used in bus fare payment system, its usage has later been expanded into a wide range of payments such as those for other public transports, car parks, government services, retail consumptions, and food and beverage services. There are currently more than three million MP Cards in issue.
The first mobile payment platform in Macau, Macau e-wallet ("MPay"), was subsequently issued by Macau Pass, it was an innovated product which led Macau into the development of e-payment. The major functions of MPay cover on-line and off-line payments, transfers, utility payments like telephone, water, electricity and gas bills and public transports. Currently over 90% of Macau residents are registered MPay users. Its cross-border operation between Hong Kong and Mainland China has been approved by the People's Bank of China and the Monetary Authority of Macao ("AMCM") in 2019, the first financial institution having offshore headquarters to be granted the right to use its offshore e-wallet across the border in Mainland China. The completion of the acquisition will create tremendous synergies to AGTech's existing businesses and broaden the revenue base of the Group through integrations along the value chain.
"As a local business, Macau Pass's years-long investment in the community and economy of Macau has borne fruitful results, and is fully recognized and highly appreciated by AGTech." praised Mr. Sun Ho, Chairman and CEO of AGTech. "Over the years, Macau Pass has been actively involving in local fintech industry, expanding its e-payment applications to different levels of Macau people's daily lives. AGTech shares Macau Pass's ideology of livelihood services-oriented. While enabling a stable transition of Macau Pass, we will cooperate with the local government to turn Macau into a smart city of the 21st century. Through innovation, we will strive to facilitate the integration of Macau Pass, and will invest more resources into integrated payment scenarios that combine on-line and off-line payments, as well as to create a hybrid platform that integrates mobile payment, e-commerce and local services for users and merchants. We will expand mobile payment services to support merchants and SMEs to leverage its advantages in order to speed up services and the development of digitization and intelligence management to meet the increasing consumer demand in the Greater Bay Area. This can provide users with stable, secure and efficient mobile payment experiences, while giving Macau our support in its next new phase of digital economy."
According to AMCM's figures published in February this year, the number of mobile payment transactions in Macau has increased from approximately 65.5 million in 2020 to approximately 193 million in 2021, representing a year-on-year increase of 194%; the total transaction value has increased from approximately MOP 6.3 billion in 2020 to approximately MOP 18.5 billion in 2021, representing a year-on-year increase of 192%. These figures showcase increasing trends in both the frequency and the transaction value of mobile payments in Macau.
"The completion of Macau Pass acquisition marks an important milestone for AGTech. It lays a solid foundation for the Group's future strategic expansion into payment business and financial services ecosystem. Under the policy of "Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area", we believe that Macau Pass will become the leader of local fintech innovation to propel the appropriate diversification of Macau's economy and the growth of local fintech industry. At the same time, it can also deepen the interconnection of mobile financial infrastructure of Macau, Greater Bay Area, Guangdong-Macao In-Depth Cooperation Zone and Mainland China. From here, we are preparing ourselves to tap into a market with 1.4 billion potential users and to jointly explore overseas opportunities and facilitate international grand economic cycle." added Mr. Sun Ho.
About AGTech Holdings Limited
AGTech was incorporated in Bermuda and its shares are listed on the GEM (Stock Code: 08279). As a member of the Alibaba Group, AGTech is the exclusive lottery platform of Alibaba Group and Ant Group.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAGTech Holdings Limited ("AGTech" or the "Group", SEHK: 08279) announced today that it has completed the acquisition of Macau Pass Holding Ltd. ("Macau Pass") and its subsidiaries, which will become an indirect wholly-owned subsidiary of AGTech after completion of the transaction.
Cheil Worldwide Inc. is a global marketing and communications agency with its headquarters based out of Seoul, South Korea. The leading advertising agency provides a variety of marketing services that include advertising, public relations, digital marketing, etc. On March 21, 2022, the DFC DAO shared a tweet regarding Cheil Worldwide’s entry into the NFT world. Samsung s advertising agency will publish NFT and launch an NFT market Cheil Worldwide, Samsung's advertising agency, announced its entry into the NFT business at a recent shareholder meeting. Cheil Worldwide will issue NFT and launch NFT trading market. — DFC DAO (@DFCDAO) March 21, 2022 Cheil Worldwide Launches Into Korean NFT Space The Samsung Group’s affiliated corporation, Cheil Worldwide has decided to step into the NFT space (non-fungible token) by issuing NFTs and launching a marketplace to trade the same NFTs as well. In addition to the abundant human resources one needs to enter the NFT marketplace, Cheil Worldwide also boasts of the experience it has in its kitty. Cheil is known to have been in charge of operations of the online shopping mall, called Third Planning. Alongside that, Cheil Worldwide has begun hiring personnel for the development of NFT or Blockchain software. As per a report by the marketing agency, it required a candidate that has the ability to work on blockchain-based design and development, issuance of NFTs, blockchain mainnet, and launching a marketplace for auctions. Future of Cheil Worldwide The objective of Cheil Worldwide is the expansion of its digital business in the present year. The expansion includes the business of NFT and the production of metaverse content. Presently, Cheil has been planning ways to flourish the country’s entertainment industry. Thus, the corporation has been promoting intellectual property from Korean drama series that include music, events, exhibitions, games turned into NFTs in the marketplace. On March 17, 2022, Cheil Worldwide CEO Yoo Jeong-Geun spoke of its marketing agency in a shareholder’s meeting, “As marketing channels like metaverse and live commerce have diversified due to the recent pandemic, the importance of tech-based content has greatly increased, and advertisers. They are concentrating their marketing on channels with practical results are continuously demanding to strengthen their efficiency.” NFT Marketplace Observes Rapid Expansion Inspired by its parent company, the Samsung subsidiary has been pushing for NFT adoption as well. As per a report, 80 percent of Asia which includes Central, Southern, and Eastern account for roughly 37 percent of global traffic to OpenSea.